GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Xebra Brands Ltd (XCNQ:XBRA) » Definitions » Debt-to-Revenue

Xebra Brands (XCNQ:XBRA) Debt-to-Revenue : 0.00 (As of Nov. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Xebra Brands Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Xebra Brands's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.00 Mil. Xebra Brands's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.00 Mil. Xebra Brands's annualized Revenue for the quarter that ended in Nov. 2023 was C$0.12 Mil. Xebra Brands's annualized Debt-to-Revenue for the quarter that ended in Nov. 2023 was 0.00.


Xebra Brands Debt-to-Revenue Historical Data

The historical data trend for Xebra Brands's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xebra Brands Debt-to-Revenue Chart

Xebra Brands Annual Data
Trend Feb20 Feb21 Feb22 Feb23
Debt-to-Revenue
N/A N/A N/A -

Xebra Brands Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xebra Brands's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Xebra Brands's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xebra Brands's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Xebra Brands's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Xebra Brands's Debt-to-Revenue falls into.



Xebra Brands Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Xebra Brands's Debt-to-Revenue for the fiscal year that ended in Feb. 2023 is calculated as

Xebra Brands's annualized Debt-to-Revenue for the quarter that ended in Nov. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Nov. 2023) Revenue data.


Xebra Brands Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Xebra Brands's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Xebra Brands (XCNQ:XBRA) Business Description

Traded in Other Exchanges
Address
1090 Hamilton Street, Vancouver, BC, CAN, V6B 2R9
Xebra Brands Ltd is focused on cannabis cultivation and products, with global brands and intellectual property. Its products cover wellness and leisure and include beverages. It has one reportable business segment, being the cultivation, processing, manufacturing, design and delivery of cannabis products.

Xebra Brands (XCNQ:XBRA) Headlines

No Headlines